Randomized, double-blind, placebo-controlled clinical study of Jiaweiyixin Decoction in the treatment of Qi deficiency and blood stasis syndrome of chronic heart failure

Early Phase 1

Completed

• Conditions: chronic cardiac failure

• Registration Number: ITMCTR2024000203
• Lead Sponsor: Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the above Western diagnostic standards and TCM syndrome differentiation standards;
2. NYHA cardiac function Grade ? and ?;
3. The primary disease was coronary heart disease and dilated cardiomyopathy.
4, aged between 65 and 80 years old;
5. Did not participate in other drug clinical studies within 1 month before inclusion;
6. Sign informed consent.

Exclusion Criteria

1. Heart failure after acute myocardial infarction;
2. EF > 50%;
3. Increased mortality associated with cardiogenic shock, severe ventricular arrhythmia, complete atrioventricular block, constrictive pericarditis, pericardial tamponade, pulmonary embolism, etc.;
4. Patients with severe primary diseases such as liver, kidney, hematopoietic system, abnormal kidney function, and severe mental illness;
5, uncontrolled infection, hypertension, etc.;
6. Allergy or known allergy to therapeutic drugs.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified